Brokers Set Expectations for MCRB Q2 Earnings

Seres Therapeutics, Inc. (NASDAQ:MCRB) – Research analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of Seres Therapeutics in a research report issued on Tuesday, June 23rd. HC Wainwright analyst M. Keller expects that the biotechnology company will earn ($2.07) per share for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. HC Wainwright also issued estimates for Seres Therapeutics’ Q3 2026 earnings at ($0.90) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($5.84) EPS, FY2027 earnings at ($2.87) EPS and FY2028 earnings at ($3.03) EPS.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($2.08) EPS for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $0.36 million.

Several other analysts have also recently weighed in on the company. Canaccord Genuity Group reissued a “buy” rating and set a $22.00 price objective on shares of Seres Therapeutics in a report on Friday, March 13th. Weiss Ratings lowered shares of Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Finally, Wall Street Zen upgraded shares of Seres Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 6th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $17.00.

Seres Therapeutics Stock Up 6.8%

Seres Therapeutics stock opened at $7.05 on Wednesday. The business’s 50-day simple moving average is $7.46 and its 200 day simple moving average is $10.67. The stock has a market cap of $68.24 million, a price-to-earnings ratio of -1.36 and a beta of 0.13. Seres Therapeutics has a 12-month low of $5.31 and a 12-month high of $29.98.

Institutional Investors Weigh In On Seres Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MCRB. Goldman Sachs Group Inc. boosted its holdings in Seres Therapeutics by 40.9% during the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock worth $52,000 after buying an additional 21,679 shares during the last quarter. Invesco Ltd. increased its stake in shares of Seres Therapeutics by 193.2% in the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 89,995 shares during the last quarter. Bank of America Corp DE raised its position in shares of Seres Therapeutics by 2,772.6% in the 3rd quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock valued at $103,000 after acquiring an additional 5,157 shares during the period. Barclays PLC raised its position in shares of Seres Therapeutics by 427.8% in the 4th quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock valued at $111,000 after acquiring an additional 6,024 shares during the period. Finally, ExodusPoint Capital Management LP bought a new position in Seres Therapeutics during the 4th quarter worth approximately $190,000. Institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.